11:51, Friday, 23 June 2006
Sydney - Friday - June 23: (RWE Aust Business News) - Dia-B Tech
Ltd (ASX:DIA) expects to begin clinical trials of its ISF402
anti-diabetes compound in the last quarter of 2006 after initial trials
on animals proved that the compound is effective in lowering blood
glucose levels.
Chairman Dr Michael Wooldridge said this milestone now allows the
company to prepare the appropriate protocols and documentation for
regulatory approvals to commence Phase 1 human trials after the
completion of mandatory animal toxicity studies to be completed during
August.
"Dia-B is excited with the progress of ISF402 as an oral drug
that can enhance insulin action to reduce glucose in the blood stream of
the body, and to potentially benefit type 2 diabetes sufferers world
wide," he said.
DIA
dia-b tech limited
11:51, Friday, 23 June 2006 Sydney - Friday - June 23: (RWE Aust...
Add to My Watchlist
What is My Watchlist?